Achieved LDL cholesterol levels in patients with heterozygous familial hypercholesterolemia: AÂ model that explores the efficacy of conventional and novel lipid-lowering therapy

Less than 10% with and 50% of heFH patients without CHD would reach treatment targets with maximal dose statin, but this substantially increases on addition of ezetimibe, CETPi, or PCSK9i. However, considering recently published adherence data, this might be lower in real life, especially in heFH patients with CHD.